Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab

Osamu Matsuno; Seijiro Minamoto

doi:10.1016/j.rmcr.2019.100899

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab

Respir Med Case Rep. 2019 Jul 9:28:100899. doi: 10.1016/j.rmcr.2019.100899. eCollection 2019.

Authors

Osamu Matsuno¹, Seijiro Minamoto¹

Affiliation

¹ Department of Medicine for Allergic Disease, Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka, 583-8588, Japan.

Abstract

We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-induced eosinophil reduction; thus, prior favorable responses to mepolizumab may predict benralizumab efficacy.

Keywords: ACT, Asthma control test; BT, bronchial thermoplasty; Benralizumab; CT, computed tomography; Eosinophil; FEV1, expiratory volume in 1 second; FVC, forced vital capacity; FeNO, fraction of exhaled nitric oxide; ICS, inhaled corticosteroids; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene antagonist; Mepolizumab; Severe asthma.

Publication types

Case Reports